Alector, Inc.

NASDAQ•ALEC

CEO: Dr. Arnon Rosenthal Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2019-02-07

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

連絡先情報

131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, 94080, United States

415-231-5660

www.alector.com

時価総額

$242.80M

PER (TTM)

-1.6

17.9

配当利回り

52週高値

$3.40

52週安値

$0.87

52週レンジ

53%

順位40Top 42.0%

4.1

F-Score

改良版 Piotroski 分析

9年ファンダメンタル

堅調 • 4.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2017-2025

財務ダッシュボード

Q4 2025 データ

売上高

$6.24M+0.00%

直近4四半期の推移

EPS

-$0.34+0.00%

直近4四半期の推移

フリーCF

-$41.69M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Nivisnebart Phase 2 Enrollment Complete Nivisnebart Phase 2 enrollment complete for early AD; independent interim futility analysis planned for first half 2026.

Cash Runway Through 2027 Cash, equivalents, securities total $256.0M, providing operational runway extending at least through 2027 based on current plans.

R&D Expenses Decreased R&D expenses fell $62.9M to $123.1M, driven by AL002 program termination and wind-down activities post-2024.

Pipeline Advancing Toward IND AL137 targeting IND submission Q4 2026 or Q1 2027; AL050 GCase therapy IND submission targeted for 2027.

リスク要因

Net Loss Widened Substantially Net loss reached $(142.9M) in 2025, up $23.9M from prior year, reflecting high ongoing development costs.

Collaboration Revenue Decline Collaboration revenue dropped $79.5M to $21.0M, primarily from satisfaction of AL002 and latozinemab obligations.

Significant Workforce Reduction Workforce reduced by 47% in October 2025 to align resources; restructuring charges totaled $7.3M in 2025.

Need for Future Capital Requires substantial additional financing to complete development and commercialization efforts across the entire preclinical and clinical pipeline.

見通し

Awaiting Nivisnebart Trial Data Awaiting PROGRESS-AD trial results; independent interim futility analysis for nivisnebart safety and efficacy is scheduled for first half 2026.

Advancing Preclinical Candidates Targeting IND submission for AL137 in late 2026/early 2027; AL050 GCase program IND submission targeted for 2027.

Resource Alignment Strategy Workforce reduced by 47% in late 2025 to better align resources with strategic priorities moving forward.

Evolving ABC Platform Continue refining proprietary Alector Brain Carrier (ABC) platform for enhanced brain delivery across multiple therapeutic modalities.

同業比較

売上高 (TTM)

SCPH

$49.97M

+107.8%

VYGR

$40.37M

-49.5%

ALEC

$21.05M

-79.1%

粗利益率 (最新四半期)

APLT

100.0%

+0.0pp

ACIU

100.0%

+0.0pp

VYGR

93.2%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CAPR	$1.39B	-17.0	-71.0%	11.5%
ANNX	$676.91M	-4.1	-92.3%	11.8%
LRMR	$393.29M	-2.7	-91.8%	2.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

19.3%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月30日

EPS:-$0.28

売上高:$9.67M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし